Edition:
India

Biogen Inc (BIIB.OQ)

BIIB.OQ on NASDAQ Stock Exchange Global Select Market

264.77USD
1 Jul 2020
Change (% chg)

-- (--)
Prev Close
$264.77
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
838,429
52-wk High
$374.94
52-wk Low
$215.81

Select another date:

Fri, Jun 19 2020

U.S. court rules in favor of Mylan over Biogen's key MS drug patent

A U.S. district court on Thursday ruled in favor of generic drugmaker Mylan NV in a patent dispute over Biogen Inc's blockbuster multiple sclerosis drug, Tecfidera, sending Biogen's shares down nearly 6%.

U.S. court rules in favor of Mylan over Biogen's key MS drug patent

A U.S. district court on Thursday ruled in favor of generic drugmaker Mylan NV in a patent dispute over Biogen Inc's blockbuster multiple sclerosis drug, Tecfidera, sending Biogen's shares down nearly 6%.

UPDATE 2-U.S. court rules in favor of Mylan over Biogen's key MS drug patent

June 18 A U.S. district court on Thursday ruled in favor of generic drugmaker Mylan NV in a patent dispute over Biogen Inc's blockbuster multiple sclerosis drug, Tecfidera, sending Biogen's shares down nearly 6%.

BRIEF-Biogen Says To Appeal Court Decision Regarding Patent Related To Tecfidera

* BIOGEN SAYS WILL APPEAL THE DECISION BY U.S. DISTRICT COURT REGARDING PATENT RELATING TO TECFIDERA Further company coverage:

BRIEF-U.S. District Court Finds Mylan Has Convincing Evidence That Asserted Claims By Biogen For Patent Associated With Tecfidera Are Invalid

* U.S. DISTRICT COURT FINDS MYLAN HAS CONVINCING EVIDENCE THAT ASSERTED CLAIMS BY BIOGEN FOR PATENT ASSOCIATED WITH TECFIDERA ARE INVALID

U.S. district court rules for Mylan in MS drug patent battle with Biogen

June 18 A U.S. district court on Thursday ruled in favor of generic drugmaker Mylan NV in a patent dispute over Biogen Inc's blockbuster multiple sclerosis drug Tecfidera, sending the drugmaker's shares down 7%.

BRIEF-Biogen Says Data Shows Early, Sustained Treatment With Spinraza Enabled Unprecedented Survival In Infants With SMA

* NEW RESULTS FROM LANDMARK NURTURE STUDY SHOW THAT PRE-SYMPTOMATIC SMA PATIENTS TREATED WITH SPINRAZA® (NUSINERSEN) CONTINUE TO DEMONSTRATE SUSTAINED BENEFIT FROM TREATMENT

BRIEF-Biogen Presents Positive Cutaneous Lupus Erythematosus Data At Eular

* BIOGEN PRESENTS POSITIVE PHASE 2 CUTANEOUS LUPUS ERYTHEMATOSUS (CLE) DATA AT EUROPEAN E-CONGRESS OF RHEUMATOLOGY (EULAR) 2020

BRIEF-Biogen Says Director Lynn Schenk Will Retire From Board At End Of Her Current Term

* BIOGEN INC - DIRECTOR LYNN SCHENK WILL RETIRE FROM BOARD AT END OF HER CURRENT TERM Source text for Eikon: Further company coverage:

BRIEF-Vir Biotechnology And Biogen Execute Agreement To Manufacture Sars-Cov-2 Antibodies For Potential Covid-19 Treatment

* VIR BIOTECHNOLOGY AND BIOGEN EXECUTE AGREEMENT TO MANUFACTURE SARS-COV-2 ANTIBODIES FOR POTENTIAL COVID-19 TREATMENT

Select another date: